ReviewJournal of the Royal Society, Interface2012
Biomaterial strategies for alleviation of myocardial infarction.
Review in Journal of the Royal Society, Interface, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 212 citations in OpenAlex.
- Osteogenic Differentiation Properties of BLGFs/ODEX Hydrogel Doped With Collagen Derived FromInternational journal of biomaterials · 2026Article
- Injectable Peptide Hydrogels Loaded with Murine Embryonic Stem Cells Relieve IschemiaBiomacromolecules · 2024Article
- The Current State of Extracellular Matrix Therapy for Ischemic Heart Disease.Medical sciences (Basel, Switzerland) · 2024Review
- Tissue poromechanical deformation effects on steam pop likelihood in 3-D radiofrequency cardiac ablation.Journal of biological engineering · 2023Article
- Spatial distribution and network morphology of epicardial, endocardial, interstitial, and Purkinje cell-associated elastin fibers in porcine left ventricle.Bioactive materials · 2023Article
- Electrically conductive carbon-based (bio)-nanomaterials for cardiac tissue engineering.Bioengineering & translational medicine · 2023Review
- Engineering approaches for cardiac organoid formation and their characterization.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Development and Characterization of Furfuryl-Gelatin Electrospun Scaffolds for Cardiac Tissue Engineering.ACS omega · 2022Article
- Nanomaterial-Based Electrically Conductive Hydrogels for Cardiac Tissue Repair.International journal of nanomedicine · 2022Review
- Chitosan as Functional Biomaterial for Designing Delivery Systems in Cardiac Therapies.Gels (Basel, Switzerland) · 2021Review
- Designing a 3D Printing Based Auxetic Cardiac Patch with hiPSC-CMs for Heart Repair.Journal of cardiovascular development and disease · 2021Article
- Evaluation of Therapeutic Collagen-Based Biomaterials in the Infarcted Mouse Heart by Extracellular Matrix Targeted MALDI Imaging Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2021Article
- Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction.Cells · 2021Review
- Biomimetic reduced graphene oxide coated collagen scaffold for in situ bone regeneration.Scientific reports · 2021Article
- Role of induced pluripotent stem cells in diagnostic cardiology.World journal of stem cells · 2021Review
- Injectable Myocardial Matrix Hydrogel Mitigates Negative Left Ventricular Remodeling in a Chronic Myocardial Infarction Model.JACC. Basic to translational science · 2021Article
- Optimizing Anisotropic Polyurethane Scaffolds to Mechanically Match with Native Myocardium.ACS biomaterials science & engineering · 2020Article
- Collagen biomaterial for the treatment of myocardial infarction: an update on cardiac tissue engineering and myocardial regeneration.Drug delivery and translational research · 2019Review
- Reduced graphene oxide: osteogenic potential for bone tissue engineering.IET nanobiotechnology · 2019Article
- Cardiac fibrosis: potential therapeutic targets.Translational research : the journal of laboratory and clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
World Health Organization estimated that heart failure initiated by coronary artery disease and myocardial infarction (MI) leads to 29 per cent of deaths worldwide. Heart failure is one of the leading causes of death in industrialized countries and is expected to become a global epidemic within the twenty-first century. MI, the main cause of heart failure, leads to a loss of cardiac tissue impairment of left ventricular function. The damaged left ventricle undergoes progressive 'remodelling' and chamber dilation, with myocyte slippage and fibroblast proliferation. Repair of diseased myocardium with in vitro-engineered cardiac muscle patch/injectable biopolymers with cells may become a viable option for heart failure patients. These events reflect an apparent lack of effective intrinsic mechanism for myocardial repair and regeneration. Motivated by the desire to develop minimally invasive procedures, the last 10 years observed growing efforts to develop injectable biomaterials with and without cells to treat cardiac failure. Biomaterials evaluated include alginate, fibrin, collagen, chitosan, self-assembling peptides, biopolymers and a range of synthetic hydrogels. The ultimate goal in therapeutic cardiac tissue engineering is to generate biocompatible, non-immunogenic heart muscle with morphological and functional properties similar to natural myocardium to repair MI. This review summarizes the properties of biomaterial substrates having sufficient mechanical stability, which stimulates the native collagen fibril structure for differentiating pluripotent stem cells and mesenchymal stem cells into cardiomyocytes for cardiac tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.